{"id":"W4281627747","doi":"10.1200/jco.2022.40.16_suppl.7516","title":"Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Internal medicine; Neutropenia; Cohort; Oncology; Cancer; Toxicity; Gastroenterology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001004522,0.001000865,0.001457092,0.0003893243,0.0003351028,0.0006891303,0.0005644716,0.000727159,0.00233704],"category_scores_gemma":[0.0005804437,0.0005590279,0.001140629,0.0003308636,0.0006115271,0.000856244,0.0002793347,0.001858847,0.0006137154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001129849,"about_ca_system_score_gemma":0.001344794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001245513,"about_ca_topic_score_gemma":0.00402654,"domain_scores_codex":[0.9997391,0.0001067074,0.00001517711,0.0000510753,0.00002510769,0.00006277961],"domain_scores_gemma":[0.9996521,0.00005425417,0.00006298152,0.00002624894,0.00001973375,0.0001844873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7330086,0.07730078,0.01703207,0.001330721,0.002457503,0.0004457752,0.0004704592,0.002287427,0.03051727,0.0002370741,0.003119365,0.1317928],"study_design_scores_gemma":[0.4965794,0.4729601,0.02361624,0.00005767434,0.000735713,0.0003376172,0.00008683761,0.0009105569,0.001557756,0.0001698345,0.002958062,0.00003021175],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943618,0.00231819,0.0002547571,0.0001970777,0.00009093509,0.001390211,0.0003949571,0.00004559879,0.0009465195],"genre_scores_gemma":[0.9948325,0.001417737,0.0006661118,0.0004943312,0.0001350167,0.0009797359,0.0005809243,0.00001000554,0.0008836648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00233704,"threshold_uncertainty_score":0.008197665,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1358988903056127,"score_gpt":0.470248609626649,"score_spread":0.3343497193210363,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}